US Pharma MarketingThe post Syntis Bio announces Phase I/Ib data for SYNT-101 in obesity appeared first on Clinical Trials Arena.
Syntis Bio announces Phase I/Ib data for SYNT-101 in obesity
Syntis Bio has reported results from the MAD segment of its Phase I/Ib SYNTIETY-1 trial of SYNT-101, an oral therapy for the potential obesity treatment. SYNT-101 was tolerated at all dose levels, with no participant withdrawals or dose reductions. SYNT-101 is an oral therapy intended for the potential treatment of obesity. Credit: Monkey Business Images / Shutterstock.com. Syntis Bio has reported results from the multiple ascending dose (MAD) segment of its Phase I/Ib SYNTIETY-1 trial of SYNT-101, an oral therapy for the potential obesity treatment. The 28-day study, involving 23 overweight or obese adults, evaluated changes in metabolic markers and…
Syntis Bio has reported results from the MAD segment of its Phase I/Ib SYNTIETY-1 trial of SYNT-101, an oral therapy for the potential obesity treatment.
Source: Clinical Trials Arena